On Wednesday, May 10, 2017, the Medical Imaging Drugs Advisory Committee (MIDAC) supported, by a vote of 11-Yes to 0-No, with no abstentions, the safety and efficacy of 5-aminolevulinic acid (5-ALA), powder for oral solution, by NX Development Corp. (NXDC) for use as an imaging agent during glioma surgery.